A. Higdon

Anti-Coxsackievirus B3 neutralizing antibodies with pathological potential.

C. Gauntt, H. Arizpe, M. Rozek, 1991, European heart journal.

Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis.

D. Bowers, C. Gauntt, H. Arizpe, 1995, Journal of immunology.

Changes in Prostate-Specific Antigen (PSA) Level Correlate with Growth Inhibition of Prostate Cancer Cells Treated in Vitro with a Novel Anticancer Drug, Irofulven

R. Muñoz, S. Waters, B. Woynarowska, 2004, Investigational New Drugs.

Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF).

J. Woynarowski, J. Macdonald, B. Woynarowska, 2000, Biochemical pharmacology.

In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.

M. Sarosdy, C. Demoor, A. Higdon, 1996, The Journal of urology.

Specific and Nonspecific Heart Defenses in Enteroviral Infections

B. McManus, N. Chapman, S. Tracy, 1993 .

What lessons can be learned from animal model studies in viral heart disease?

D. Bowers, C. Gauntt, E. Maull, 1993, Scandinavian journal of infectious diseases. Supplementum.

Epitopes shared between coxsackievirus B3 (CVB3) and normal heart tissue contribute to CVB3-induced murine myocarditis.

S. Tracy, C. Gauntt, H. Arizpe, 1993, Clinical immunology and immunopathology.